The Aenova Group, one of the world’s leading CDMO companies for the pharmaceutical and healthcare industry, announces the company’s new organizational structure: with the three new business units Solids, Semi Solids & Liquids and Softgel Capsules, the company’s 15 manufacturing sites will be organized to focus on the business areas with high growth potential. The Solids BU is headed by SVP Christine Beck, the Semi Solids & Liquids BU by SVP Florent Bordet and the Softgel Capsules BU by SVP Michael Ammann. At the same time, the newly established cross-divisional functions Development Services & Tech Transfer, Business Development & Strategy, Global Quality, Continuous Improvement, Engineering and Communication & PR support the corporate
strategy of the Aenova Group, which is geared towards excellence and expansion.
Responsible for the strategy is the Executive Leadership Team (ELT) around CEO Jan Kengelbach and CFO Ralf Schuler. The Aenova Group, with around 4,300 employees worldwide, is one of the major contract manufacturers for the pharmaceutical and dietary supplements industry and supports its customer companies along the entire value chain, from development and production to packaging of all important dosage forms and product groups for human and animal health.
The speciality of the Aenova Group is the wide range of production and packaging specialities – tablets, dragees, suppositories, hardgel and softgel capsules, sterile liquids in ampoules, vials, in blisters or bottles, etc. -, which the 15 individual sites produce and package with many years of experience. In addition, the Aenova Group’s Development Services offer their customers support in the preparation of clinical studies: from the production of clinical study material, analysis and galenics to packaging and distribution of the samples to the respective study centres. The transfer of technologies also counts in this area, which is now managed by Head Dr. Jörg Gampfer. The new business unit structure bundles the service fields of the Aenova Group strategically
and sustainably. “We are thus concentrating on the essential areas of our core business, optimizing and accelerating decision-making, bundling competencies and streamlining our portfolio according to dosage forms and technologies”, explains Jan Kengelbach, CEO of the Aenova Group. The newly established corporate divisions are responsible for centrally overlapping tasks:
Global Quality with SVP Dr Macniell Esua, Corporate HSES with VP Dr Pedro Diaz Kraus, Business Development & Strategy with Head Dr Matthias Groh, Commercial Excellence with BVP Dr Volker Viktor and Communications & PR with Head Dr Susanne Knabe. “In order to give our ambitions for operational excellence even more clout within our corporate strategy, we need experts in our Corporate and Support Functions. The Aenova Group is one of the major players in the CDMO market worldwide. We want to expand this position”, adds Jan Kengelbach.
Among the Contract Development and Manufacturing Organizations (CDMO) the Aenova Group is the sixth largest player internationally and in Europe the number one in many areas. The Aenova Group has long-standing customer relationships with many large pharmaceutical companies around the globe. “At the Aenova Group we are aware that the products we manufacture help improve the health and well-being of millions of patients around the world. With our new business unit structure and corporate functions, we underpin our commitment to customers and patients and continue to focus on highest quality, operational excellence and delivery reliability. I wish our colleagues every success in their work,” says Jan Kengelbach